Market Overview

Global Cancer/Tumor Profiling Market Report 2017 Analysis & Forecasts 2013-2023 - Rising Utility of Biomarkers in Tumor Profiling


DUBLIN, March 20, 2018 /PRNewswire/ --

The "Cancer/Tumor Profiling Market by Technology, by Technique, by Application, by Geography - Global Market Size, Share, Development, Growth and Demand Forecast, 2013-2023" report has been added to's offering.

Research and Markets Logo

The boost in demand for cancer/tumor profiling products is mainly led by increasing number of new cancer cases, rising utility of biomarkers in tumor profiling, rising availability of funding for cancer research and increasing demand for next generation sequencing for cancer profiling.

The cancer profiling market has been bifurcated into next generation sequencing (NGS), quantitative polymerase chain reaction (QPCR), immunohistochemistry (IHC), in-situ hybridization (ISH), and microarray, based on technology. NGS held the largest share in the cancer profiling market, standing at 33.1%, in 2016. This leading position of NGS is mainly characterized by increased awareness about NGS products due to rising promotional activities for these products among the research laboratories and academic institutes. The NGS category is also expected to grow at the highest CAGR during the forecast period.

ISH is further categorized into fluorescent in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). FISH held the larger share of the ISH technology market in 2016. The higher penetration of this technology is driven by increasing number of players offering FISH in cancer profiling market, such as Abbott Laboratories. FISH is also expected to observe the faster growth in future, with the CAGR likely to stand at 18.6% during the forecast period.

The various techniques used in the cancer profiling include genomics, proteomics, epigenetics, and metabolomics. Genomics held the largest share of 40.6% in 2016, and it is also expected to register highest growth during the forecast period, due to increasing implementation of genomic sequencing.

Cancer profiling is used in varied applications such as personalized medicine, diagnostics, biomarker discovery, prognostics, and others. In 2016, personalized medicine held largest share of 36.4% in the cancer profiling market, attributed to subsequent increasing adoption of personalized medicine for tumor profiling, since it is one of the most cost-effective methods. The application is also expected to register fastest growth during the forecast period.

The Asia-Pacific cancer profiling market has been experiencing significant growth due to rising prevalence of cancer, increasing government initiatives for cancer treatment, and rising healthcare expenditure in the region. According to the Indian Council of Medical Research (ICMR), around 14.5 lakhs of new cancer cases were registered in India in 2016, which is likely to reach nearly 17.3 lakh new cases, by 2020. This increase in cancer cases indicates that, the healthcare providers will require more profiling kits, thus increasing the demand for cancer/tumor profiling kits in the region.

Globally, the key providers in the cancer profiling market are launching new products to gain a larger market share. In October 2017, QIAGEN N.V. launched custom solutions business, aimed at providing life sciences and molecular diagnostics companies with the tools and expertise required to quickly build and commercialize products that meet unique workflow requirements. In the same month, the company also launched ipsogen JAK2 RGQ PCR kit, an ipsogen JAK2 assay, an assay used for the detection of the JAK2 V617F/G1849T allele in genomic DNA extracted from EDTA whole blood.

Some of the other key players operating in the cancer profiling market include Illumina, Inc., NeoGenomics Inc., Caris Life Sciences, Inc., Helomics Corp., Oxford Gene Technology, HTG Molecular Diagnostics, Inc., RiboMed Biotechnologies, Inc., Genomic Health, Inc., and NanoString Technologies, Inc.

Market Dynamics


  • Increasing Number of New Cancer Cases
  • Rising Utility of Biomarkers in Tumor Profiling
  • Rise in Availability of Funding for Cancer Research
  • Increasing Demand for Next Generation Sequencing for Cancer Profiling
  • Impact Analysis of Drivers on Market Forecast


  • High Capital Investments and Low Benefit Ratio for Biomarkers
  • Dearth of Skilled Professionals and Infrastructure
  • Impact Analysis of Restraints on Market Forecast


  • Increasing Use of Point-of-Care Diagnostic Tests
  • Rising Demand for Personalized Medicine

Key Topics Covered

Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Research Scope
1.3.1 Market Segmentation by Technology
1.3.2 Market Segmentation by Technique
1.3.3 Market Segmentation by Application
1.3.4 Market Segmentation by Geography
1.3.5 Analysis Period
1.3.6 Market Data Reporting Unit Value
1.4 Key Stakeholders

Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents By region By industry participant By company type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction
4.1 Definition of Market Segments
4.1.1 By Technology NGS QPCR IHC ISH FISH CISH Microarray
4.1.2 By Technique Genomics Proteomics Epigenetics Metabolomics
4.1.3 By Application Personalized medicine Diagnostics Biomarker discovery Prognostics Others
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porter's Five Forces Analysis
4.3.1 Bargaining Power of Buyers
4.3.2 Bargaining Power of Suppliers
4.3.3 Intensity of Rivalry
4.3.4 Threat of New Entrants
4.3.5 Threat of Substitutes

Chapter 5. Global Market Size and Forecast
5.1 By Technology
5.1.1 ISH Technology by Type
5.2 By Technique
5.3 By Application
5.4 By Region

Chapter 6. North America Market Size and Forecast
6.1 By Technology
6.2 By Technique
6.3 By Application
6.4 By Country

Chapter 7. Europe Market Size and Forecast
7.1 By Technology
7.2 By Technique
7.3 By Application
7.4 By Country

Chapter 8. Asia-Pacific Market Size and Forecast
8.1 By Technology
8.2 By Technique
8.3 By Application
8.4 By Country

Chapter 9. LATAM Market Size and Forecast
9.1 By Technology
9.2 By Technique
9.3 By Application
9.4 By Country

Chapter 10. MEA Market Size and Forecast
10.1 By Technology
10.2 By Technique
10.3 By Application

Chapter 11. Global Market Size and Forecast by Technology
11.1 Global NGS Market, by Region
11.2 Global QPCR Market, by Region
11.3 Global IHC Devices Market, by Region
11.4 Global ISH Market, by Region
11.5 Global Microarray Market, by Region

Chapter 12. Global Market Size and Forecast by Technique
12.1 Global Genomics Market, by Region
12.2 Global Proteomics Market, by Region
12.3 Global Epigenetics Devices Market, by Region
12.4 Global Metabolomics Market, by Region

Chapter 13. Global Market Size and Forecast by Application
13.1 Global Personalized Medicine Market, by Region
13.2 Global Diagnostics Market, by Region
13.3 Global Biomarker Discovery Market, by Region
13.4 Global Prognostics Market, by Region

Chapter 14. Competitive Landscape
14.1 Product Benchmarking of Key Players
14.2 Global Strategic Developments of Key Players
14.2.1 Product Launches and Approvals
14.2.2 Agreements, Partnerships and Collaborations
14.2.3 Facility Expansion
14.2.4 Other Developments

Chapter 15. Company Profiles
15.1 Illumina, Inc.
15.2 NeoGenomics Inc.
15.3 Caris Life Sciences, Inc.
15.4 QIAGEN N.V.
15.5 Helomics Corp.
15.6 Oxford Gene Technology
15.7 HTG Molecular Diagnostics, Inc.
15.8 RiboMed Biotechnologies, Inc.
15.9 Genomic Health, Inc.
15.10 NanoString Technologies, Inc.

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:

SOURCE Research and Markets

View Comments and Join the Discussion!